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Bone marrow-derived endothelial
progenitor cells are a major determinant
of nascent tumor neovascularization
Daniel J. Nolan,1,4 Alessia Ciarrocchi,2 Albert S. Mellick,1 Jaspreet S. Jaggi,3 Kathryn Bambino,1
Sunita Gupta,1 Emily Heikamp,1 Michael R. McDevitt,3 David A. Scheinberg,3 Robert Benezra,2
and Vivek Mittal1,5
1Cancer Genome Research Center, Cold Spring Harbor Laboratory, Woodbury, New York 11797, USA; 2Program in Cancer
Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA; 3Program in Molecular
Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA; 4Graduate
Program in Genetics, Stony Brook University, Stony Brook, New York 11794, USA
Tumors build vessels by cooption of pre-existing vasculature and de novo recruitment of bone marrow
(BM)-derived endothelial progenitor cells (EPCs). However, the contribution and the functional role of EPCs
in tumor neoangiogenesis are controversial. Therefore, by using genetically marked BM progenitor cells, we
demonstrate the precise spatial and temporal contribution of EPCs to the neovascularization of three
transplanted and one spontaneous breast tumor in vivo using high-resolution microscopy and flow cytometry.
We show that early tumors recruit BM-derived EPCs that differentiate into mature BM-derived endothelial
cells (ECs) and luminally incorporate into a subset of sprouting tumor neovessels. Notably, in later tumors,
these BM-derived vessels are diluted with non-BM-derived vessels from the periphery, which accounts for
purported differences in previously published reports. Furthermore, we show that specific ablation of
BM-derived EPCs with -particle-emitting anti-VE-cadherin antibody markedly impaired tumor growth
associated with reduced vascularization. Our results demonstrate that BM-derived EPCs are critical
components of the earliest phases of tumor neoangiogenesis.
[Keywords: Bone marrow transplantation; tumor angiogenesis; endothelial progenitor cells; endothelial cells;
VE-cadherin; neovascularization]
Supplemental material is available at http://www.genesdev.org.
Received April 5, 2007; revised version accepted April 30, 2007.
The angiogenic switch involves the formation of new
blood vessels (neovasculature), and is a hallmark of can-
cer emergence and progression (Folkman 1971; Hanahan
and Folkman 1996; Carmeliet and Jain 2000). In adults,
neovasculature formation relies on the sprouting and co-
option of proliferating endothelial cells (ECs) from adja-
cent pre-existing host vasculature. More recent investi-
gations suggest that the adult bone marrow (BM) is a
source of cells that contributes significantly to postnatal
angiogenesis (Carmeliet 2005; Kopp et al. 2006). Of the
BM-derived cells, much focus has been directed on the
proangiogenic hematopoietic mural cells that are re-
cruited to the perivascular sites within the tumor bed
(Coussens and Werb 2002; Pollard 2004; Carmeliet 2005;
Kopp et al. 2006). Several populations of BM-derived he-
matopoietic cells have been reported to contribute to
tumor angiogenesis. These include tumor-associated
macrophages (TAMs) (Lin et al. 2001; Pollard 2004),
Tie2-expressing monocytes (TEMs) (De Palma et al.
2005), VEGF receptor 1 (VEGFR1)-positive myeloid pro-
genitors (Lyden et al. 2001), recruited BM-derived circu-
lating cells (Grunewald et al. 2006), PDGFR+ pericyte
progenitors (Song et al. 2005), vascular leukocytes
(Conejo-Garcia et al. 2005), and infiltrating neutrophils
(Nozawa et al. 2006). Despite the general importance of
these cells in tumor angiogenesis, the precise composi-
tion of specific individual lineages remains poorly under-
stood.
In addition to the perivascular contribution of BM-de-
rived hematopoietic cells, it has been proposed that the
BM-derived endothelial progenitor cells (EPCs) provide
an alternative source of ECs that contributes to neoves-
sel formation (Lyden et al. 2001; Urbich and Dimmeler
2004; Khakoo and Finkel 2005; Kopp et al. 2006). In re-
sponse to tumor cytokines, including VEGF (Asahara et
al. 1999), putative VEGFR2-positive EPCs mobilize into
the peripheral blood circulation to become circulating
endothelial progenitors (CEPs), which subsequently
move to the tumor vascular bed and incorporate into
neovessels (Lyden et al. 2001; Rafii et al. 2002). The ex-
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istence of a BM reservoir of EPCs, and their selective
involvement in neovascularization, has attracted consid-
erable interest because these cells may represent a novel
target for therapeutic intervention. However, since the
first description of EPCs (Asahara et al. 1997), their iden-
tity and relative contribution to neovasculature forma-
tion has remained controversial. Extensive variability in
EPC contribution to vessel formation has been de-
scribed. For instance, contributions as high as 50%
(Lyden et al. 2001; Garcia-Barros et al. 2003) to as low as
5%–20% (Machein et al. 2003; Rajantie et al. 2004;
Peters et al. 2005)—and, in some cases, undetectable lev-
els (De Palma et al. 2003, 2005; Voswinckel et al. 2003;
Gothert et al. 2004; He et al. 2004; Ziegelhoeffer et al.
2004)—have been reported. Such conflicting reports can
be ascribed to a limited analysis of the EPC phenotype in
each study, and a lack of more definitive methods em-
ployed for distinguishing vessel incorporated BM-derived
ECs and intimately associated perivascular cells. Yet an-
other source of variability may arise from the analysis of
specific tumor types (Ruzinova et al. 2003; Li et al. 2004),
and stages of tumor progression. Irrespective of these
variable reports, CEPs are being considered as useful sur-
rogate markers for monitoring cancer progression, as
well as for optimizing efficacy of anti-angiogenic thera-
pies, such as anti-VEGFR2 antibody therapy (Bertolini
et al. 2006).
Therefore, the aim of this study was to determine the
phenotypic identity, precise spatial and temporal contri-
bution, and functional role of BM-derived EPCs in tumor
angiogenesis. The data from our analysis show that EPCs
are recruited to the tumor periphery preceding vessel for-
mation. EPCs differentiate into ECs and incorporate lu-
minally into a subset of sprouting tumor neovessels in
various tumors. Selective ablation of EPCs in vivo re-
sulted in a marked delay in tumor growth associated
with distinct vascular defects, thereby underscoring the
functional relevance of these cells in the process of tu-
mor neovascularization.
Results
Spatial and temporal contribution of BM-derived EPCs
in the neovascularization of growing tumors
In order to determine the contribution of the BM-derived
EPCs to the formation of tumor neovasculature, we per-
formed a BM transplantation (BMT) experiment. To
track BM-derived cells in vivo, GFP+ BM cells were iso-
lated from C57BL/6-Tg (ACTbEGFP) mice and trans-
planted into lethally irradiated age-matched, syngeneic,
non-GFP recipients. Analysis of BM and peripheral blood
(4 wk post-transplantation) showed >95% reconstitution
of recipient hematopoiesis by the donor BM-derived
GFP+ transplanted progenitor cells (data not shown), in-
dicating stable replacement of original host stem cell
population by the donor cells. Next, the reconstituted
mice were challenged with intradermal tumors such as
Lewis lung carcinoma (LLC), B6RV2 lymphoma, or or-
thotopic implanted melanoma (Aozuka et al. 2004). In
addition to being syngeneic to the host, tumor implan-
tations allow precise staging during tumor growth and
minimize variability between animals.
We first determined the contribution of BM-derived
endothelial progenitors to early stages of LLC tumor
growth. Tumors were isolated, cryosectioned, and im-
munostained for EC markers (CD31/PECAM, VE-cad-
herin, VEGFR2/flk1, endoglin, and VCAM), progenitor
markers (Prominin I/AC133), and various hematopoietic
lineage markers. As expected, many BM-derived GFP+
cells were observed infiltrating the tumor bed. Interest-
ingly, at early stages of tumor growth (days 4–6), we ob-
served a marked recruitment of BM-derived GFP+ cells
expressing the endothelial marker VE-cadherin at the pe-
riphery (Fig. 1A, arrows). Noticeably, these GFP+ VE-cad-
herin+ cells were recruited to early tumors prior to vessel
invasion from the neighboring host tissue (Fig. 1A). Al-
though these cells expressed VE-cadherin, we deter-
mined that they were not mature ECs because they
lacked typical mature EC morphology, expressed uni-
form cell surface VE-cadherin (cf. VE-cadherin localized
at the adherens junctions between two adjacent mature
ECs in a vessel), and expressed low CD31 (>10-fold re-
duction relative to ECs in vessels) (Fig. 1B, arrows;
Supplementary Fig. S1A). Low CD31 expression on these
cells was further confirmed by flow cytometric analysis
of early tumors (Supplementary Fig. S1B). These cells
also expressed the endothelial-specific marker VEGFR2,
endoglin, and progenitor cell marker Prominin I/AC133
(Supplementary Fig. S2A–C), representing EPCs. Indeed,
some of these markers have been used in defining EPCs
previously (Asahara et al. 1997; Peichev et al. 2000;
Ribatti 2004; Kopp et al. 2006). The EPCs lacked expres-
sion of all hematopoietic lineage markers tested, includ-
ing CD11b (monocytes, subsets of lymphocytes, Den-
dritic cells, and NK cells), CD45RB (monocytes, granu-
locytes, and subsets of T and B cells), and CD41
(megakaryocytes) (Supplementary Fig. S3A–C). Dim
CD45 expression was observed in EPCs in the BM com-
partment but not in the tumors (data not shown). These
results are consistent with a published report that VE-
cadherin+ progenitor cells in the adult BM do not con-
tribute to the hematopoietic lineages (Kim et al. 2005). In
summary, these results demonstrate that BM-derived
EPCs are recruited to early tumors prior to vessel forma-
tion, and that the EPCs are distinct from the hematopoi-
etic lineages.
BM-derived ECs luminally incorporate into early
tumor neovessels
We next determined the contribution of BM-derived
EPCs to neovessel formation in early vascular LLC tu-
mors (days 6–8). These early vascular tumors were char-
acterized by the presence of CD31+ neovessels of various
sizes (Fig. 2A). A subset of these nascent sprouting
vessels contained incorporated BM-derived GFP+ CD31+
VE-cadherin+ cells (Fig. 2A, arrows). High-resolution
microscopic analysis of these chimeric vessels showed
that the vessel-incorporated BM-derived cells exhibited
EPCs contribute to tumor angiogenesis
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hallmarks of a mature EC such as spindle-like morphol-
ogy, high surface CD31 expression, and characteristic
VE-cadherin staining at the intercellular adherens junc-
tions (Fig. 2B). Optical sectioning (Z-stack resolution of
0.275 µm) further confirmed that the BM-derived ECs
had a single nucleus, and that the GFP and CD31 signals
were localized to the same individual cell (Fig. 2C;
Supplementary Fig. S4A), indicating that the incorpo-
rated EC was derived from the BM. Computer three-
dimensional (3D) rendering analysis confirmed that the
VE-cadherin staining was shared between the GFP+ BM-
derived EC and the non-BM-derived EC in these vessels
(data not shown). High-resolution microscopy also al-
lowed us to exclude false positives comprised of perivas-
cular GFP+ cells intimately associated with vessels
(Supplementary Fig. S4B,C), suggesting that low-resolu-
tion light microscopy may lead to the overestimation of
luminally incorporated BM-derived ECs, as reported pre-
viously (Lyden et al. 2001; Garcia-Barros et al. 2003). It is
worth noting that under all circumstances, BM-derived
ECs were found in chimeric vessels with non-BM-
derived ECs as opposed to vessels comprised exclusively
of BM-derived ECs. The BM-derived GFP+ ECs also
lacked expression of hematopoietic lineage markers in-
cluding CD11b (data not shown) and CD45 as deter-
mined by both immunostaining of tumor sections and
flow cytometry (Supplementary Fig. S5A–C). BM-derived
EPCs and vessel-incorporated ECs were also observed
during early growth phase of other tumors, including
melanomas (Supplementary Fig. S6A,B) and B6RV2 lym-
phoma (data not shown). Taken together, these results
demonstrate that in response to a tumor challenge, BM-
derived EPCs, which are distinct from proangiogenic he-
matopoietic cells, are first recruited to early tumors fol-
lowed by luminal incorporation of BM-derived ECs into
the neovessels.
We next performed flow cytometric analysis to deter-
mine the relative numbers of BM-derived EPCs (GFP+
VE-cadherin+ CD31low CD11b−) and non-BM-derived ECs
(GFP− VE-cadherin+ CD31high CD11b−) at different
stages of tumor growth (Fig. 3A). BM-derived EPCs com-
prised of 25%–35% of the total ECs in the early phases of
tumor growth (days 4–6), and this contribution decreased
about fourfold in late tumors (day 14), consistent with
histological analysis (data not shown). Notably, in late
tumors there was an enhanced recruitment of local non-
BM-derived GFP− ECs (65%–75%, days 10–14), which
diluted the observed contribution of BM-derived EPCs.
We next quantified luminally incorporated BM-derived
ECs in tumor vessels. Vessel counts from optically sec-
tioned tumors showed that ∼20% of vessels had incor-
porated BM-derived ECs (GFP+ VE-cadherin+ CD31+) at
day 6 (Fig. 3B), and these chimeric vessels markedly de-
creased with time (<1% remaining after 4 wk). As an
alternate approach to quantify luminal incorporation, we
performed systemic perfusion with fluorescently labeled
isolectin GS-IB4, which stains specific carbohydrates on
ECs (Laitinen et al. 1987). Analysis of tumor vessels with
Figure 1. BM-derived EPCs are recruited at the periphery of early tumors. (A) A representative fluorescent image showing recruitment
of BM-derived GFP+ VE-cadherin+ EPCs (arrows) at the periphery of early nonvascularized LLC tumors (days 4–6; n = 15). CD31+
mature vessels are observed in the host tissue but not in the tumors. The dotted line separates the host tissue from the tumor. Bar,
100 µm. (B) High-resolution image showing GFP+ VE-cadherin+ CD31low EPCs (arrows) at the periphery of LLC tumors (day 4). DAPI
was used to stain the nucleus of all cells. Bar, 5 µm.
Nolan et al.
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anti-CD31 antibody showed that isolectin GS-IB4 stain-
ing was confined to the functional vessels (Supplemen-
tary Fig. S7A) as compared with choleratoxin, which
leaked into the surrounding tumor tissue (Supplemen-
tary Fig. S7B). Furthermore, fluorescent isolectin specifi-
cally stained the luminal surface of endothelial cells in
vessels (Fig. 3C, arrow), and these cells could be detected
by flow cytometric analysis (Fig. 3D, top-right quadrant).
We therefore used flow cytometric analysis to determine
the percentage of luminally incorporated BM-derived
ECs in the tumor neovasculature. Of the total functional
vasculature, as determined by Lectin+ CD31+ CD11b−
cells, 31% (±8.3) of the luminal ECs (GFP+ Lectin+
CD31+ CD11b−) in day 6 LLCs (Fig. 3E) are BM derived.
A similar kinetic analysis performed in a melanoma
model also showed recruitment of EPCs prior to vessel
infiltration, early contribution of BM-derived ECs, and
their subsequent dilution by host ECs (Supplementary
Fig. S6; data not shown). A comparison of the contribu-
tion of BM-derived EPCs and ECs in different tumors is
summarized in Supplementary Table S1.
Together, these results demonstrate that BM-derived
EPCs are recruited to early avascular tumors. EPCs dif-
ferentiate into ECs and luminally incorporate into a sub-
set of sprouting peripheral vessels from the host. This is
followed by massive invasion of peripheral vasculature
into the tumor mass, diluting the BM-derived vessels at
late stages of tumor growth.
BM-derived EPCs contribute to spontaneous tumors
In order to confirm that these events are also taking
place in spontaneous tumors, we performed a similar
analysis in breast tumors arising in MMTV-PyMT trans-
genic mice (Guy et al. 1992). In these animals, the PyMT
oncogene is expressed under the transcriptional control
of the mouse mammary tumor virus promoter/enhancer
specifically in the mammary epithelium (Guy et al.
1992). The PyMT transgene activates pathways similar
to that induced by ErbB2 (Desai et al. 2002), and, impor-
tantly, this murine tumor model recapitulates human
breast cancer progression from early nonmalignant hy-
perplasia (∼6 wk of age) and adenoma (8–9 wk of age), to
early and late malignant adenocarcinoma (8–12 wk of
age) (Lin et al. 2003).
We examined the contribution of BM-derived EPCs
and luminally incorporated ECs at various stages of
these mammary tumors developing in animals previ-
Figure 2. BM-derived ECs are luminally incorporated in tumor neovasculature. (A) Representative fluorescent image showing CD31+
mature vessels in LLC tumors (days 6–8; n = 15). Arrows depict incorporated BM-derived ECs in these vessels. Bar, 200 µm. The dotted
line separates the host tissue from the tumor. (B) High-resolution image of a representative blood vessel showing an incorporated
mature BM-derived GFP+ CD31+ VE-cadherin+-coexpressing cell (arrow). The lumen of the vessel (L) and VE-cadherin staining the
adherens junctions between ECs are shown. Bar, 20 µm. (C) Optical sectioning (Z-stack resolution, 0.275 µm) of the BM-derived ECs
showing that GFP and CD31 signals are localized within the same individual cell (X–Z- and Y–Z-axes are represented by the top and
side panels).
EPCs contribute to tumor angiogenesis
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ously transplanted with GFP+ BM. Early adenomas (∼8
wk of age) were identified as closely packed multifocal
acini surrounded by pre-existing host vessels (Fig. 4A,
arrows). Adenomas at this stage had not yet recruited
neovasculature from the pre-existing vessels, and very
few GFP+ BM cells were observed infiltrating the ad-
enoma mass (Fig. 4A). A subset of adenomas progressing
into early carcinoma showed foci of BM-derived GFP+
cells including EPCs (Fig. 4B, arrows). Such foci of BM-
derived cell infiltration have been previously observed in
adenomas (Lin et al. 2003). Analysis of early carcinomas
(10 wk of age) showed high density of BM infiltration and
increased vessel density. These vascular tumors were
characterized by the presence of CD31+ neovessels of
various sizes (Fig. 4C). These sprouting nascent vessels
had incorporated BM-derived GFP+ CD31+ ECs (Fig. 4C).
In this model, quantitation of luminally incorporated
BM-derived ECs by flow cytometry was technically
challenging due to the closely packed, multifocal na-
ture of breast tumor development. We therefore per-
formed vessel counts by microscopy of early carcinomas,
which showed that ∼5%–10% of host vessels had incor-
porated BM-derived GFP+ ECs (GFP+ VE-cadherin+
CD31+) (Fig. 4E).
The observation that BM-derived EPCs precede host
ECs and that BM-ECs contribute to neovascularization
in early stages of breast tumor progression is consistent
with that observed in transplanted tumors, highlighting
the general relevance of these cells in tumor neovascu-
latization.
Figure 3. Contribution of BM-derived EPCs and ECs as a function of tumor progression. (A) Flow cytometry analysis of LLC tumors
(days 4–14; n = 5 per group), showing relative contribution of BM-derived EPCs (GFP+ VE-cadherin+ CD31low, CD11b−), and host-
derived ECs (GFP− VE-cadherin+ CD31+, CD11b−). Total number of cells analyzed was 2 × 105 per animal, except for day 4, due to
smaller tumor size. Each analysis was performed in duplicate. Error bars represent standard deviations. This experiment was repeated
three times, and identical trends were observed. (B) Quantification of vessels in LLC tumors (days 4–28) with incorporated BM-derived
ECs (GFP+, CD31+, VE-cadherin+), a minimum of 400 vessels counted per time point from six nonsequential sections, and 20 images
per tumor (Z-stacks evaluated for each section). Error bars represent standard deviations. (C) A representative image showing a tumor
vessel from an animal perfused with isolectin GS-IB4 and stained with CD31. Arrows indicate isolectin IB4 staining the luminal
surface of the EC in the vessel. (L) Lumen. Bar, 20 µm. (D) Flow cytometric analysis of LLC tumors (days 6–8) showing that fluorescent
isolectin specifically stains a population of luminally incorporated CD31+ ECs. (E, left) Flow cytometric analysis showing that
fluorescent isolectin stains a population of luminally incorporated ECs (CD31+ CD11b−) derived from LLC tumors. (Right) Of these,
31% ± 8.3% are BM derived (GFP+ CD31+ Isolectin+ CD11b−). The averages and standard deviation were determined by analyzing
1 × 105 cells per animal (n = 5). (SSC-A) Side scatter values.
Nolan et al.
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BM-derived EPCs differentiate into ECs
and incorporate into vessels
We next sought to formally demonstrate that BM-de-
rived EPCs have the potential to differentiate into ma-
ture ECs and incorporate into neovessels. First, we
sorted GFP+ EPCs (Lin− VE-cadherin+) from the BM by
flow cytometry (Fig. 5A), and cocultured them with
spontaneously immortalized murine ECs, mHEVc
(Cook-Mills et al. 1996), in matrigel. Notably, mHEVcs
in culture have lost CD31 and VE-cadherin expression,
but have retained VCAM expression (Cook-Mills et al.
1996). By 12 h, VE-cadherin+ EPCs had not differentiated
into ECs and remained VCAM-negative (Fig. 5B). How-
ever, by day 2, GFP+ BM-ECs that had incorporated into
the growing vascular networks were detected (Fig. 3D,
top panel). These incorporated GFP+ BM-derived ECs
expressed VCAM (Fig. 5C, bottom panel) and CD31
(Supplementary Fig. S8A). High-resolution microscopy
confirmed that the incorporated EC was indeed derived
from the GFP+ EPC (Supplementary Fig. S8B). We next
determined whether the EPCs recruited to early tumors
differentiated into ECs and incorporated into neovessels.
GFP+ VE-cadherin+ CD11b− cells were flow sorted from
early tumors (day 4) (Fig. 5D). EPCs identified as
CD31low (as depicted in Supplementary Fig. S1B), were
cocultured with mHEVcs in matrigel. By day 2, GFP+
EPCs had differentiated into GFP+ ECs and incorporated
into the vascular networks (Fig. 5E). In contrast, GFP+
CD11b+ hematopoietic cells isolated from the same
early tumors neither differentiated into ECs nor incor-
porated into vessels (Fig. 5F). Collectively, these results
demonstrate that BM-derived VE-cadherin+ EPCs con-
tribute to the endothelial lineage.
Specific ablation of EPCs results in defects
in angiogenesis-mediated tumor growth
To determine if the BM-derived EPCs had a functional
role in angiogenesis-mediated tumor growth, we selec-
tively ablated EPCs with an anti-VE-cadherin antibody,
E4G10. The monoclonal antibody E4G10 specifically
recognizes the exposed monomeric epitope on the im-
mediate N terminus of VE-cadherin, which becomes
masked upon trans-dimerization in mature ECs in ves-
Figure 4. Contribution of BM-derived EPCs in spontaneous breast tumors. (A) Primary adenoma lesions in mammary gland sections
from a PyMT mouse at 8 wk of age. Pre-existing CD31+ vessels are observed surrounding the adenomas. Bar, 100 µm. (B) Recruitment
of BM-derived GFP+ VE-cadherin+ EPCs (arrows) at the periphery of the avascular adenoma–carcinoma progression is shown. Bar, 100
µm. (C) An early carcinoma showing recruited CD31+ mature vessels in the tumor mass (10 wk of age). Arrow depicts incorporated
BM-derived ECs in a vessel. Bar, 100 µm. (D) High-resolution image of a representative blood vessel (box in C) showing an incorporated
mature BM-derived GFP+ CD31+-coexpressing cell (arrow). Bar, 20 µm. DAPI was used to stain the nucleus of all cells. (E) Quantifi-
cation of vessels in breast tumors (10 wk old) with incorporated BM-derived ECs (GFP+ CD31+ VE-cadherin+). A minimum of 250
vessels were counted from nonsequential sections from four animals, and Z-stacks were evaluated for each section. Error bars represent
standard deviations.
EPCs contribute to tumor angiogenesis
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sels (May et al. 2005). Thus, E4G10 allows targeting of
monomeric VE-cadherin present on EPCs, but not the
dimerized form present in vessel incorporated ECs. We
confirmed that E4G10 recognizes VE-cadherin only on
the EPCs, but not in mature ECs comprising the nascent
early tumor neovessels (Fig. 6A, white arrows; Supple-
mentary Fig. S9), compared with a pan-VE-cadherin an-
tibody 11D4.1 (VE-cadhpan) that recognized both the mo-
nomeric VE-cadherin on EPCs and homodimerized VE-
cadherin on ECs in vessels (Fig. 6A, red arrows). In
addition, the VE-cadherin epitope was exposed in neither
the luminally incorporated BM-derived GFP+ ECs (data
not shown) nor the EC projections of sprouting nascent
vessels in early tumors (Fig. 6B,C).
The cytotoxic potency of E4G10 was enhanced by cou-
pling the antibody to an -particle-emitting isotope, ac-
tinium-225 (225Ac) (McDevitt et al. 2001), so that target
cells could be effectively killed at low concentrations of
the antibody. Administration of 225Ac-labeled E4G10
(50 nCi, 0.6 µg antibody per administration per animal)
reduced accumulated LLC tumor burden per animal by
∼50% (day 14, P = 0.001) compared with the administra-
tion of equivalent amounts of 225Ac-labeled IgG iso-
type control mixed with unlabeled E4G10 (Fig. 7A). The
impaired tumor growth was associated with a marked
reduction in EPC contribution (>45%, P = 0.004) as de-
termined by flow cytometry (Fig. 7B) and confirmed by
histology (Supplementary Fig. S10). Ablation of VE-cad-
herin+ cells was specific, since no detectable change was
observed in other BM-derived GFP+ infiltrating cell
populations, including the CD11b+ hematopoietic cells
available in the immediate proximity (P = 0.86) (Fig. 7C).
Notably, ablation of VE-cadherin+ EPCs resulted in a
40% reduction in BM-derived luminally incorporated
ECs (GFP+ CD31+ Isolectin+ CD11b−) (P = 0.016) (data
not shown), and a dramatic reduction in vessel density
Figure 5. BM-derived EPCs differentiate into mature ECs and incorporate into vascular networks. (A) Scatter plot showing VE-
cadherin-expressing EPCs in the BM-derived Lin− CD11b− fraction (green box). (B) Immunostaining of cocultured BM-derived GFP+
EPCs and mature ECs (non-GFP) in 3D matrigel at 12 h. (Right panels) A high-resolution image showing an unincorporated, BM-
derived GFP+ VCAM− EPC (white arrow). (C) Multiple BM-derived ECs (GFP+ VCAM+, yellow arrows) that have incorporated into
vascular tubes 48 h following coculture. (Right panels) A high-resolution image showing an incorporated BM-derived GFP+ EC (yellow
arrow). (D) Scatter plot showing GFP+ cells from day 4 LLC tumors. GFP+ VE-cadherin+ CD11b− EPCs (green box) and GFP+ VE-
cadherin− CD11b+ hematopoietic cells (blue box) were live-sorted. (E) Immunostaining of the cocultured BM-derived GFP+ EPCs sorted
in D and mature ECs (non-GFP) in 3D matrigel at 48 h. High-resolution microscopy showing an incorporated BM-derived GFP+ VCAM+
EC (yellow arrow). (F) Immunostaining of the cocultured GFP+ CD11b+ hematopoietic cells sorted in D and mature ECs (non-GFP) in
3D matrigel at 48 h. High-resolution microscopy showing an unincorporated BM-derived GFP+ VCAM− cell (white arrow). Bars, 10 µm.
(SSC-A) Side scatter values.
Nolan et al.
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(P = 0.006) in later tumors (Fig. 7D,E). No gross or histo-
pathological toxicity was observed in normal tissues or
their vasculature at the dosage administered (data not
shown). Taken together, these results suggest that abla-
tion of EPCs results in marked delay in tumor growth
associated with decreased vessel density.
Discussion
In this study, we provide evidence that BM-derived
EPCs, as defined by the cell surface expression of VE-
cadherin, VEGFR2, CD31low, Endoglin, and Prominin
I/AC133 (Supplementary Table S2), differentiate into
mature ECs and contribute both structurally and func-
tionally to tumor neoangiogenesis. Further analysis
demonstrated that the EPCs are distinct from other he-
matopoietic and proangiogenic BM-derived cell types
such as TEMs (De Palma et al. 2005), macrophages (Pol-
lard 2004), recruited BM-derived circulating cells
(Grunewald et al. 2006), pericyte progenitors (Song et al.
2005), and infiltrating neutrophils (Nozawa et al. 2006).
The BM-derived ECs are also distinct from vascular leu-
kocytes (Conejo-Garcia et al. 2005), because they do not
express leukocyte marker CD45 (Supplementary Fig. S5).
Analysis of multiple tumor types showed that EPCs
differentiate into mature ECs and luminally incorporate
into neovessels, clearly demonstrating the derivation of
tumor vasculature from transplanted BM cells. A sys-
tematic kinetic analysis showed that EPCs are recruited
to the tumor periphery preceding vessel formation, and
are luminally incorporated into a subset of sprouting tu-
mor neovessels. Noticeably, these chimeric BM-derived
vessels were eventually diluted with host-derived ves-
sels, thereby explaining the low contribution observed
by other investigators in large, established tumors (De
Palma et al. 2003, 2005; Gothert et al. 2004; Rajantie et
al. 2004; Larrivee et al. 2005; Duda et al. 2006). Possibly,
de Palma et al. (2003) were unable to detect BM-derived
tumor ECs not only due to the analysis of late tumors (4
wk), but also because the Tie2 promoter in their study
does not mark all the Tie2+ mature ECs or bona fide
EPCs. In their study, the reporter GFP gene was not
driven by the endogenous Tie2 promoter. Instead, the
Figure 6. VE-cadherin monoclonal antibody E4G10 specifically recognizes EPCs and not mature ECs. (A) Five-color immunostaining
of early LLC tumors (day 6) with VE-cadherin antibody E4G10 (white arrows), pan-VE-cadherin antibody 11D4.1 (VE-cadhpan, red
arrows), and CD31. E4G10 exclusively staining EPCs is shown (double red and white arrows). Bar, 20 µm. (B) Immunostaining of early
tumors (day 6) with CD31 and a pan-VE-cadherin antibody. Low-magnification image showing endothelial projections of the invading
tumor vasculature. Yellow arrows depict VE-cadherin+ EPCs in the vicinity. Bar, 20 µm. GFP staining is not included for precise
visualization. (C) Higher magnification of the area denoted by a rectangle in B, showing that the endothelial projections are devoid of
VE-cadherin (white arrows).
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Tie2 promoter driving the GFP gene was introduced by a
lentiviral construct into murine embryonic stem cells.
Therefore, it is possible that random integration of len-
tiviral vectors may have failed to identify the true re-
populating EPCs. In a similar study, using an endothe-
lial-specific (SCL) inducible Cre recombinase to activate
a stop-floxed -galactosidase gene, Gothert et al. (2004)
argue the lack of BM-precursor contribution to the tu-
mor endothelium. The SCL promoter does not mark the
progenitors in the BM, but was used to identify BM-de-
rived cells that mature in the periphery. The lack of
LacZ+ peripheral vessels observed at 14 d post-implanta-
tion is in agreement with our data that BM-derived chi-
meric vessels are diluted by mature peripheral vessels in
later tumors.
Our results differ from those of Garcia-Barros et al.
(2003), and Lyden et al. (2001), who reported 50%–90%
BM-derived CD31+ vessels in large established tumors as
estimated by X-gal staining in LacZ+ BM transplants.
Possibly, X-gal detection by light microscopy may im-
pose difficulty in reliably distinguishing vessel-incorpo-
rated ECs from closely associated perivascular cells, re-
sulting in overestimation of BM-derived vessels. Since
these reports were published, the use of high-resolution
confocal microscopy for the accurate determination of
vessel incorporated ECs has been advocated (De Palma et
al. 2003; Larrivee et al. 2005). Indeed, in this study we
have demonstrated that 3D high-resolution microscopy
is required to accurately discern luminally incorporated
ECs from perivascular cells (Supplementary Fig. S4B,C).
Our data are in disagreement with those of Spring et al.
(2005), who showed derivation of BM-derived neovessels
as a late event in carcinogenesis. In these studies, flow
cytometric analysis of CD31+ GFP+ cells does not pro-
vide a reliable measure of vessel-incorporated BM-de-
rived ECs. Luminal incorporation by flow cytometry
can be more reliably quantitated in the context of spe-
cific isolectin administration and analysis of Isolectin+
CD31+ GFP+ CD11b− cells (Fig. 3). GFP determines BM
derivation, isolectin ensures luminal incorporation,
CD31 confirms ECs, and CD11b gates out any hemato-
poietic contribution in the CD31 channel. This approach
is critical because CD31 is also expressed by a subset of
hematopoietic cells (Baumann et al. 2004), and therefore
the use of CD31 alone provides an unreliable measure of
bona fide ECs.
Evidence for the contribution of EPCs to ischemic re-
vascularization resulting from severe vascular injury has
Figure 7. Selective ablation of EPCs results in delayed tumor growth in vivo. (A) LLC tumor volume at day 14 in animals admin-
istered with isotype control 225Act-IgG and unlabeled E4G10 or 225Act-E4G10 antibody (n = 5, 10 per group, respectively). (B) Number
of BM-derived EPCs (GFP+ VE-cadherin+ CD31low CD11b−) cells in early tumors (day 6) in animals administered with control or
225Act-E4G10 antibody at day 3 and 5 post-tumor innoculation (n = 5, 10, respectively; 1 × 105 events counted per n). Bars denote
averages. (C) BM-derived GFP+ CD11b+ cells in tumors from animals treated as in B (n = 5, 10, respectively; 1 × 105 events counted per
n). Bars denote averages. (D) Vessel density in tumors in animals treated with control and test antibody (day 14; n = 5, 7 per group,
respectively) (E) CD31 immunostaining of tumor sections (day 14) isolated from E4G10-treated and control-treated animals. Bar,
50 µm. Error bars represent standard deviations. (*) Significant by t-test; P < 0.05.
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been reported both in humans and mice. For example,
Minami et al. (2005) have shown that circulating ECs
engraft luminally into 15%–29% of the vessels of the
transplanted heart in patients with sex-mismatched
heart transplants. These data suggest that during acute
vascular injury, the demand for neoangiogenesis in-
creases to a point where there is a profound contribution
of circulating host-derived ECs to neoangiogenesis. Simi-
larly, during the angiogenic switch, as it may occur in
the early phases of tumor growth, the rapid demand for
neoangiogenesis may facilitate the recruitment of BM-
derived EPCs, as observed in our investigation. The pres-
ence of EPCs in tumors prior to recruitment of host vas-
culature raises the possibility that the BM-derived EPCs
may play a critical role in initiating the recruitment of
non-BM-derived vessels to the tumors. At this stage,
EPC differentiation and luminal incorporation of BM-
derived EC may be necessary for providing structural
support and guidance to these nascent vessels. Decipher-
ing the mechanisms governing the dynamic interactions
between the BM-derived EPCs and non-BM ECs will re-
quire further investigations.
The specific recruitment to and association of EPCs
with the neovasculature of both spontaneous and trans-
planted tumors in our studies highlight the general rel-
evance of these cells in tumor angiogenesis. The func-
tional significance of EPCs in angiogenesis-mediated tu-
mor growth was determined by their effective and
selective ablation with a radiolabeled anti-VE-cadherin
antibody. Strikingly, EPC ablation resulted in decreased
vessel density and reduced tumor growth, suggesting
that the contribution of BM-derived ECs is critical for
angiogenesis-mediated tumor progression. To address
the possibility that EPCs carrying the radioactive anti-
VE-cadherin antibody may have destroyed other proan-
giogenic cells in trans via a bystander effect, we quanti-
tated other cell types observed in the proximity of the
EPCs. Radiolabeled E4G10 administration caused no de-
tectable change in BM-derived GFP+ infiltrating cells,
including the CD11b+ hematopoietic cells that are avail-
able in the immediate proximity. This result strongly
argues against the possibility of a bystander effect. In
addition, our data are in agreement with the notion that
short-ranged -emitting 225Ac atoms are capable of kill-
ing individual cells with minimal collateral damage (Mc-
Devitt et al. 2001; Borchardt et al. 2003).
Interestingly, Lamszus et al. (2005) have shown that
the administration of E4G10 on day 1 post-tumor chal-
lenge resulted in significant inhibition of angiogenesis
and tumor growth. In contrast, administration of E4G10
during later tumor growth did not effect either vessel
density or tumor growth, suggesting that the tumor phe-
notype resulted from blocking peak EPC contribution
and not from targeting differentiated ECs in established
vasculature, consistent with our data. Our results and
interpretation of the specificity of E4G10 differ from
those of Liao et al. (2002). In these studies, the authors
showed that systemic administration of 1000 µg of fluo-
rescent E4G10 (cf. 0.6 µg in our experiments) stained a
subset of tumor vasculature. Perhaps excessive antibody
administration in their experiments resulted in non-
specific binding to the permeable tumor vasculature and
the tumor stroma. In our study, we clearly demonstrated
that the VE-cadherin epitope is not exposed on invad-
ing nascent vessels in early tumors. Our observations
are in agreement with various independently published
reports demonstrating that VE-cadherin is rapidly inter-
nalized and degraded in proliferating/migrating ECs
(Xiao et al. 2003; Lampugnani et al. 2006), and show-
ing that VE-cadherin is not critical for the formation of
nascent vasculature, but is required to maintain or
prevent the disassembly of nascent blood vessels (Crosby
et al. 2005). Possibly, the suppression of tumor growth
observed by Liao et al. (2002) may have resulted as a
result of EPC blockade, which the authors did not inves-
tigate.
The clinical implications of BM-derived ECs in angio-
genesis-mediated tumor growth are further bolstered by
their recent identification in the vasculature of human
tumors (Peters et al. 2005). In this study of human sex-
mismatched BM transplant recipients who later devel-
oped tumors, fluorescence in situ hybridization analysis
showed that ∼2%–12% of ECs infiltrating the tumors
were derived from the BM (Peters et al. 2005). Perhaps, in
these studies low BM-EC contribution was estimated
due to analysis of rare archived late human tumor biop-
sies. Peters et al. (2005) may have missed the early peak
contribution of BM-derived ECs in these late tumors.
Thus, inhibition of the function of these EC progenitors,
perhaps in combination with existing anti-angiogenic
therapies, may provide a promising approach to blocking
neoangiogenesis in rapidly growing tumors, rebounding
tumors, or regrowing tumors following incomplete sur-
gical removal of a primary lesion. Furthermore, as dem-
onstrated recently, EPC targeting can also enhance the
efficacy of other anti-cancer therapies, such as vascular
disruptive agents (Shaked et al. 2006). Indeed, our ability
to delay angiogenesis-mediated tumor growth by ablat-
ing BM progenitor cells identifies these cells as promis-
ing therapeutic targets.
Materials and methods
Cell lines and growth conditions
The murine lymphoma cell line B6RV2 (Lyden et al. 2001), LLC
cell line LLCs/D122 (provided by Lea Eisenbach, Wiesmann In-
stitute of Science, Rehovot, Israel), and melanoma cell line
B16F0 (American Type Culture Collection) were used to gener-
ate tumors in C57BL/6 mice. LLCs and B16F0 were maintained
in DMEM supplemented with 10% fetal bovine serum (FBS).
B6RV2 cells were maintained in RPMI with 15% FBS. Murine
ECs, mHEVc, were cultured as described (Cook-Mills et al.
1996; Tudor et al. 2000).
Spontaneous tumor model
Male PyMT mice (obtained from mouse models of human can-
cer consortium; NCI) on a FVB/N background were randomly
bred with FVB/N females (Jackson Laboratories) lacking the
PyMT transgene to obtain female mice heterozygous for the
EPCs contribute to tumor angiogenesis
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PyMT transgene. These female carriers developed mammary
tumors by 5–6 wk, which were staged according to Lin et al.
(2003). All procedures involving mice were conducted in accor-
dance with protocols reviewed and approved by the CSHL Ani-
mal Care and Use Committee.
BM isolation, Lin− cell purification, and transplantation
GFP transgenics, C57BL/6-Tg (ACTbEGFP)10sb/J, or FVB.Cg-Tg
(GFPU)5Nagy/J (The Jackson Laboratory), were used as the do-
nor strain. In these strains, GFP is driven by a hybrid chicken
-actin promoter and cytomegalovirus intermediate early en-
hancer. BM cells were harvested by flushing the femurs and
tibias of adult animals. Total BM cells (1 × 107) were trans-
planted into lethally irradiated (1100 rads) recipients. Lin− cells
were enriched using the Lineage Cell Depletion Kit (CD5,
CD45R [B220], CD11b, anti-Ly-6G [Gr-1], 7-4, and Ter119 anti-
bodies) and a magnetic separation device, MACS (Milteyni Bio-
tech). The purity of the Lin− fraction was determined using a
fluorescent antibody specific for lineage-specific markers by
flow cytometry. All animal protocols were reviewed and ap-
proved by the CSHL Animal Care and Use Committee.
Flow cytometry, tumor growth, immunohistochemistry,
and microscopy
C57BL/6 mice were inoculated intradermally with 5 × 106 to
2 × 107 LLC/D122 or B6RV2 cells, or with 5 × 105 B16F0 cells,
and tumor size was monitored (width × 0.5 length2).
Tumors were excised from sacrificed animals, minced, and
then digested for 45–60 min at 37°C with an enzyme cocktail
(Collagenase A, elastase, and DNase I; Roche Applied Science),
and filtered through a 30-µm strainer. Single-cell suspensions
were preblocked with Fc block (CD16/CD32; BD Biosciences
PharMingen) and then incubated with the following primary
antibodies from Pharmingen: rat IgG2a and IgG2a isotype
control; CD31/PECAM-1 (clone MEC 13.3); VE-cadherin/CD144
(clone 11D4.1); CD11b (clone M1/70.); VEGFR2/Flk1 (clone
avas121). Labeled cell populations were measured by a LSRII
flow cytometer (Beckton Dickenson); compensation for multi-
variate experiments was performed with FACS Diva software
(Becton Dickinson Immunocytometry Systems). Flow cytom-
etry analysis was performed using a variety of controls such as
isotype antibodies, FMO samples (Perfetto et al. 2004), and un-
stained samples for determining appropriate gates, voltages, and
compensations required in multivariate flow cytometry. Tu-
mor-bearing mice were anesthetized and then perfused with
phosphate buffer followed by 4% paraformaldehyde. In some
cases, animals were injected with Alexa Fluor 647-conjugated
isolectin GS-IB4 or Choleratoxin  subunit (50 µg for 10 min;
Molecular Probes) prior to phosphate buffer perfusion. Tumors
were incubated overnight in paraformaldehyde, followed by
20% sucrose, and were cryoembedded in Tissue-tek O.C.T. em-
bedding compound (Electron Microscopy Sciences). Immuno-
histochemistry was performed using the primary antibodies
Prominin1 (clone 13A4; eBiosciences), Endoglin (clone MJ7/18),
CD45RB (clone 16A), pan-CD45 (clone 30-F11), CD41 (clone
MWREQ30; BD Pharmingen), and E4G10 (ImClone), in addition
to antibodies described for flow cytometry on 30-µm-thick sec-
tions. Usually, primary antibodies were directly conjugated to
various Alexa Fluor dyes or Quantum Dots using antibody la-
beling kits (Inivtrogen) performed as per the manufacturer’s in-
structions. In the case of Alexa Fluor 750, conjugations were
performed using succinimidyl esters and purified over BioSpin
P30 Gel (Bio-Rad). GFP-positive cells were detected by their
own signal.
Fluorescent images of endothelium that contained donor-
derived ECs were obtained using a computerized Zeiss fluores-
cent microscope (Axiovert 200M), fitted with an apotome and a
HRM camera. Images were analyzed by using Axiovision 4.5
software. The average depth of the optical sections was 30 µm,
with a resolution of 0.275–0.35 µm.
EPC differentiation assay
Total BM cells from GFP transgenic animals were first enriched
for Lin− cells as described before. Lin− cells were incubated with
VE-cadherin (Alexa Fluor 647) and CD11b (Alexa Fluor 750)
antibodies. Using multivariate flow sorting, a pure GFP+ EPC
population (VE-cadherin+ CD11b−) was collected by FACS Aria
(BD Biosciences). Approximately 5000 EPCs were cocultured
with 5 × 104 murine ECs, mHEVc (gift from J.M. Cook-Mills,
University of Cincinnati, Cincinnati, OH) on matrigel (BD Bio-
sciences) supplemented with Medium 200 and LSGS (Cascade
Biologics). Similarly, EPCs (1 × 103) and hematopoietic cells
(∼5 × 104) were flow-sorted from early tumors (day 4) derived
from GFP+ BMT animals and cocultured with 5 × 104 murine
ECs. Low CD31 expression on EPCs was confirmed with a PE-
conjugated CD31 antibody. Immunostaining was performed di-
rectly on matrigels with VCAM (clone 429, MVCAM.A; BD
Pharmingen) and CD31/PECAM-1 (clone MEC 13.3) antibody
after fixation with 4% paraformaldehyde.
Preparation and administration of radioimmunoconjugate
225Ac (Oak Ridge National Laboratory) was conjugated to
E4G10 (a gift from ImClone) using a two-step labeling method,
as described (McDevitt et al. 2002; Borchardt et al. 2003).
Radiopurity and immunoreactivity of the radioimmunoconju-
gate (RIC) were determined as described (Borchardt et al. 2003).
Mice were anesthetized and injected intravenously with the
RIC in 100 µL at days 3, 5, 8, and 12 (50 nCi, 0.6 µg antibody per
administration).
Statistical analysis
Analysis of different treatment groups was performed using the
Mann-Whitney T-test.
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